Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial-Reference-Cited by-同舟云学术

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Published:2024-09 Issue:9 Volume:25 Page:1202-1212
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Bührer Emanuel,Kicinski Michal,Mandala Mario,Pe Madeline,Long Georgina V,Atkinson Victoria,Blank Christian U,Haydon Andrew,Dalle Stéphane,Khattak Adnan,Carlino Matteo S,Meshcheryakov Andrey,Sandhu Shahneen,Puig Susana,Schadendorf Dirk,Jamal Rahima,Rutkowski Piotr,van den Eertwegh Alfonsus J M,Coens Corneel,Grebennik Dmitri,Krepler Clemens,Robert Caroline,Eggermont Alexander M M

Funder

Merck Sharp and Dohme K.K.

MSD

Publisher

Elsevier BV

Reference24 articles.

1. A review of cancer immunotherapy: from the past, to the present, to the future;Esfahani;Curr Oncol,2020

2. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma;Wolchok;J Clin Oncol,2022

3. Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma;Eggermont;NEJM Evid,2022

4. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial;Ascierto;Lancet Oncol,2020

5. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial;Luke;Lancet,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measuring success of adjuvant treatment for patients with melanoma;The Lancet Oncology;2024-09

2. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial;European Journal of Cancer;2024-09